Optimal first line therapy for rare kidney cancer variants (non-clear cell):  Immunotherapy

Primo N. Lara, Jr., MD Director, UC Davis Comprehensive Cancer Center Professor of Medicine and Executive Associate Dean UC Davis School of Medicine at the Kidney Cancer Association International Meeting, Miami FL November 15, 2019

Read the full article here

Related Articles